• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Abrocitinib is more effective than dupilumab for treatment of moderate-to-severe atopic dermatitis

byNeel MistryandTeddy Guo
August 2, 2022
in Chronic Disease, Dermatology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The co-primary endpoints at weeks 2 and 4 were significantly greater with abrocitinib than dupilumab.

2. Overall incidence of adverse events, such as nausea and acne, were more common with abrocitinib but were mostly mild in severity.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Topical therapy is often considered a first-line option for management of moderate-to-severe atopic dermatitis. However, when topical therapies are not sufficient, systemic therapies are often recommended. Dupilumab, an anti-interleukin [IL]-4 receptor antibody, and abrocitinib, a Janus-kinase [JAK] 1 inhibitor, are two systemic therapies that may play a role in managing atopic dermatitis. However, until now, few studies have compared the relative efficacies of these therapies. This randomized controlled trial aimed to compare the safety and efficacy of abrocitinib versus dupilumab for management of moderate-to-severe dermatitis. The primary outcome was improvement in severity, defined by an improvement of 4 or more points on the Peak Pruritus Numerical Rating Scale (PP-NRS4) at week 2 and 90% or more improvement in Eczema Area and Severity Index (EASI-90) at week 4. According to study results, a greater proportion of patients in the abrocitinib group achieved the primary endpoint compared with dupilumab. Although overall adverse events more common in the abrocitinib group, most events were considered mild in severity. There were no differences in the rate of serious adverse events between groups. A major strength of this study was that it included participants from various countries, including individuals of different race. This adds to the external validity of results.

Click to read the study in The Lancet

Relevant Reading: Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

RELATED REPORTS

#VisualAbstract: Topical Delgocitinib Cream is Super to Oral Alitretinoin Capsules in Adults with Severe Chronic Hand Eczema

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

In-depth [randomized-controlled trial]: From Jun 11, 2020, and Dec 16, 2020, 940 patients were screened for eligibility across 151 sites in 15 different countries. Included were patients ≥ 18 years of age with atopic dermatitis for ≥ 6 months and either 1) use of systemic oral therapy in last 12 months or 2) inadequate response to topical therapy within past 6 months. Altogether, 727 patients (362 in abrocitinib group and 365 in dupilumab group) were enrolled. Patients received abrocitinib (200 mg per day) or subcutaneous dupilumab (300 mg every 2 weeks) for total 26 weeks with matching placebos in both groups. The primary outcome of PP-NRS4 at week 2 (48%, 95% confidence interval [CI] 43.0-53.4 vs. 26%, 95% CI 15.8-29.5, p<0.0001) and EASI-90 at week 4 (29%, 95% CI 23.8-33.2 vs. 15%, 95% CI 10.9-18.2), p<0.0001) was significantly greater in the abrocitinib group than in the dupilumab group, respectively. Abrocitinib was associated with more adverse events (268 of 362 patients, 74%) compared to dupilumab (239 of 365, 65%). Notably, mild nausea (19% vs. 2%) and acne or folliculitis (13% vs. 3%) were more common with abrocitinib than dupilumab, respectively. Findings from this study suggest that abrocitinib is more efficacious than dupilumab in adults with moderate-to-severe atopic dermatitis.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: abrocitinibatopic dermatitisdermatologydupilumabEczemamoderate-to-severe atopic dermatitis
Previous Post

Vaccination after recovery from COVID-19 reduced rate of reinfection by half

Next Post

Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes

RelatedReports

#VisualAbstract: Topical Delgocitinib Cream is Super to Oral Alitretinoin Capsules in Adults with Severe Chronic Hand Eczema
StudyGraphics

#VisualAbstract: Topical Delgocitinib Cream is Super to Oral Alitretinoin Capsules in Adults with Severe Chronic Hand Eczema

May 1, 2025
Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain
Chronic Disease

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

March 13, 2025
Increased risk of subsequent melanoma after first melanoma diagnosis
Dermatology

Neoadjuvant ipilimumab plus nivolumab improves event-free survival in stage III melanoma

December 12, 2024
No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer
Chronic Disease

Use of certain biologics or disease modifying antirheumatic drugs may be associated with cancer risk

November 30, 2024
Next Post

Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes

#VisualAbstract: Vitamin D supplementation does not reduce the risk of incident fractures among healthy adults

#VisualAbstract: Vitamin D supplementation does not reduce the risk of incident fractures among healthy adults

Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Comparison of systemic corticosteroids with and without nebulized budenoside for management of severe acute asthma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
  • The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave
  • Early acetaminophen use reduces mortality risk in patients with sepsis-associated encephalopathy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.